

References

I-9146

1. Nucala prescribing information. GlaxoSmithKline LLC. January 2022.
2. Cinqair prescribing information. Teva Respiratory, LLC. February 2020.
3. Fasenra prescribing information. AstraZeneca Pharmaceuticals LP. February 2021.
4. International European Respiratory Society (ERS)/American Thoracic Society (ATS) Guidelines on Management of Severe Asthma. *Eur Resp J*. 2020;55:1900588. Available at <https://erj.ersjournals.com/content/55/1/1900588>.
5. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2022. Available at www.ginasthma.org.
6. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force Recommendations for Evaluation and Management. *Eur J Intern Med*. 2015;26(7):545-553.
7. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 Criteria for the Classification of Churg-Strauss Syndrome (Allergic Granulomatosis and Angiitis). *Arthritis Rheum*. 1990;33(8):1094-1100.
8. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg-Strauss Syndrome. *Medicine (Baltimore)*. 1984;63(2):65-81.
9. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
10. Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: A Phase 3, Randomized, Placebo-Controlled Trial. *J Allergy Clin Immunol*. 2020. <https://doi.org/10.1016/j.jaci.2020.08.037>.
11. Valent P, Klion AD, Horny HP, et al. Contemporary Consensus Proposal on Criteria and Classification of Eosinophilic Disorders and Related Syndromes. *J Allergy Clin Immunol*. 2012;130(3):607-612.
12. Shomali W, Gotlib J. World Health Organization-Defined Eosinophilic Disorders: 2019 Update on Diagnosis, Risk Stratification, and Management. *Am J Hematol*. 2019;94(10):1149-1167.
13. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the Treatment of Hypereosinophilic Syndromes: A Workshop Summary Report. *J Allergy Clin Immunol*. 2006;117(6):1292-1302.

14. Kuang FL, Klion AD. Biologic Agents for the Treatment of Hypereosinophilic Syndromes. *J Allergy Clin Immunol Pract*. 2017;5(6):1502-1509.
15. Stevens WW, Schleimer RP, Kern RC. Chronic Rhinosinusitis with Nasal Polyps. *J Allergy Clin Immunol Pract*. 2016;4(4):565–572.
16. Sedaghat AR. Chronic Rhinosinusitis. *Am Fam Physician*. 2017;96(8):500-506.
17. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2 suppl):S1-S39. Reaffirmed by American Academy of Family Physicians April 2020.
18. Orlandi, RR, Kingdom, TT, Smith, TL, et al. International consensus statement on rhinology and allergy: rhinosinusitis. *Int Forum Allergy Rhinol*. 2021; 11: 213– 739. <https://doi.org/10.1002/alr.22741>
19. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 Focused updates to the asthma management guidelines. National Heart, Lung, and Blood Institute, 2007. Available at: <https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines>